207 results about "Recombineering" patented technology

The invention relates to escherichia coli CGMCC NO.3192 for recombined engineering and a variant thereof. The strain is obtained by integrating gene segments subjected to the recombined engineering, i.e. a regulatory gene araC of the Arabinose ara operon from the escherichia coli, a promoter pBAD of the Arabinose ara operon from the escherichia coli, recombined enzyme genes red alpha, red alpha beta and gam from a gamma bacteriophage, a gene recA and gentamicin resistance gene (Gm) from the escherichia coli, into an endA gene area of a gene group of the escherichia coli DH10B, wherein red alpha, red alpha beta, gam and recA are driven by pBAD induced by arabinose. The recombined enzyme can catalyze homologous recombination among DNA short segments to finish the recombined engineering. The length of the DNA segment is about 50 base pairs. The invention has convenient operation of carrying out the recombined engineering by the strain and high recombined efficiency, thereby becoming the universal strain for the recombined engineering.

The invention discloses a glutamate decarboxylase mutant with improved enzyme activity and application thereof. The glutamate decarboxylase coding gene from bacillus megatherium is subjected to site-specific mutagenesis, and the catalytic performance of the obtained mutant is obviously improved compared with that of a wild type mutant. A recombinant engineering strain is constructed on the basis of the mutant, gamma-aminobutyric acid is prepared by taking a large amount of fermentation product L-glutamic acid as a substrate through a whole-cell catalysis method, the maximum yield of gamma-aminobutyric acid reaches 625.6 g/L, the molar conversion rate in a catalytic system is close to 100%, and no by-product is produced. The glutamate decarboxylase mutant disclosed by the invention has a very wide application prospect in efficient production and preparation of gamma-aminobutyric acid.

The invention discloses a carbonyl reductase expressed recombination engineering bacterium and application thereof. The engineering bacterium comprises a host cell and a recombinant vector transferred into the host cell, wherein the recombinant vector consists of an original vector and a target gene connected into the original vector, the host cell is Escherichiacoli Rosetta (DE3), the target gene is a carbonyl reductase gene, and the base sequence is shown in SEQ ID NO.1. According to the recombination engineering bacterium, the expression level of a carbonyl reductase is high, bacterial cells which are prepared through induced culture are used for converting N,N-dimethyl-3-oxy-3-(2-thienyl)-l-propylamine hydrochloride into (S)-N,N-dimethyl-3-hydroxy-3-(2-thienyl)-l-propylamine or converting 4-chloroethyl acetoacetate into (S)-4-chloro-3-hydroxyethyl butyrate, and the two products are higher in both optical purity and conversion rate.

The invention discloses a gene for coding a glutamine dipeptide biosynthetic enzyme and application thereof. The nucleotide sequence of the gene is shown as SEQ ID NO.1. The invention further discloses an amino acid sequence coded by the gene, and provides a recombinant vector containing the gene, recombinant escherichia coli, and a method for performing biotransformation to synthesize the glutamine dipeptide by using the gene. The gene and the application of a recombinant bacterial strain of the gene have the advantages of high mol conversion rate, high reaction speed, easy separation, low cost and the like. In the synthesis method, the maximum mol conversion rate of the glutamine dipeptide can reach 83.3 percent; meanwhile, the thalli can be applied to the catalytic synthesis of the glutamine dipeptide again after the circulation recovery; in addition, the catalytic activity is stable. Therefore high market competitive power and application values are realized; a foundation is laid for the industrial production of the glutamine dipeptide.

The invention discloses recombinant engineering bacteria for efficiently expressing human growth hormone (hGH), a construction method and an application and provides an escherichia coli operon for expressing recombinant hGH, an expression plasmid containing an operon sequence and engineering bacteria QJSW-SZ01 (CGMCC No:7258) used for secretory expression of the recombinant hGH and obtained by transformation of the expression plasmid containing the operon. The recombinant engineering bacteria are characterized in that a coding sequence of a signal peptide of an escherichia coli heat-stable enterotoxin is changed, and rare codons of escherichia coli in the coding sequence are mutated so as to avoid formation of a secondary structure; meanwhile, an amino acid is altered on the terminal of the coding sequence so that the coding sequence is more beneficial to guidance of secretory expression of hGH; the signal peptide, an escherichia coli alkaline phosphatsae promoter (phoA promoter) and an escherichia coli T7 terminator are combined to be used as an expression control element so that the recombinant hGH is efficiently secretory-expressed in the escherichia coli in a soluble form. The recombinant engineering bacteria lay the foundation of finally developing a low-cost hGH pharmaceutical product.

The invention provides the expression and the purification of a recombinant fusion protein, particularly a fusion protein of the tumor blood vessel targeted polypeptide and tissue factor and a preparation method and application thereof. The preparation method of the fusion protein of the tumor blood vessel targeted polypeptide and tissue factor comprises the following steps: designing primers, carrying out PCR (polymerase chain reaction) to amplify an recombinant gene of the fusion protein EG3287-tTF, guiding the recombinant gene of the fusion protein EG3287-tTF into a carrier, guiding a recombinant carrier into a host cell, constructing a recombinant engineering bacteria for expressing the fusion protein EG3287-tTF, fermenting to culture, and separating and purifying fermentation liquor to obtain the fusion protein of the tumor blood vessel targeted polypeptide and tissue factor. The targeted antitumor fusion protein EG3287-tTF is constructed, a novel tTF derivative with the antitumor advantage of the tTF and the targeting effect is obtained, the antitumor effect of the tTF is improved, and a foundation is laid to the development of a novel medicament for the targeted therapy of the tumor blood vessel.

The invention provides a method for producing L-tyrosine recombinant engineering bacteria and application of the recombinant engineering bacteria. The method comprises the following steps: taking escherichia coli SyBE-002447 as a starting strain and integrating total chemical synthesis modules Plac-aroG-tyrA-aroE and Ptrc-pps-tkt-glk respectively, so as to construct a chassis strain SyBE-22002 ofL-tyrosine; then integrally inserting a total chemical synthesis module Ptacs-hpaBC-ldh into a nupG downstream position on a chromosome, so as to obtain a strain SyBE-22011. By adopting the method provided by the invention, the problem that antibiotics and an induction agent isopropyl-beta-D-thiopyrangalactoside need to be added in a fermentation process is solved, and the L-tyrosine and tanshinolcan be efficiently produced; a downstream separation and purification process is simplified and the industrial production cost is reduced; pollution, caused by the antibiotics and the induction agent, to the environment is avoided and the economic benefits are improved.

The invention discloses a nitrilase mutant and application thereof in preparation of nicotinic acid. The mutant can be used for mutating phenylalanine at position 168 of an amino acid sequence shown in SEQ ID NO: 2 into valine and serine at position 192 into phenylalanine. A wet cell obtained by induced expression of a recombinant bacterial strain containing an itrilase mutant encoding gene is used as an enzyme source, 3-cyanopyridine is used as a reaction substrate, and a PBS buffer with pH of 7.0 is used as a reaction medium to form a reaction system, a reaction is carried out in a 40 DEG C water bath, and the nicotinic acid is obtained after the reaction is finished.

The invention relates to a method for performing gene knockout on pseudomonas putida KT2440 by a recombinant engineering measure. The method comprises the following specific steps of: amplifying through an overlapped-extension polymerase chain reaction so as to obtain a deoxyribonucleic acid (DNA) fragment of which both sides are provided with target genes to be knocked, the upstream and downstream are provided with homologous genes of about 500 base pairs and the middle is provided with a kanamycin resistance gene; electrically transforming the DNA fragment into a pseudomonas putida KT2440 electro-transformation competent cell which is expressed by toluic acid induction recombinase with the final concentration of 2mM; and replacing the target genes by the kanamycin resistance gene through homologous recombination between homologous fragments of a recombinase mediate so as to directly obtain a mutant strain from which target genes are knocked. The method is simple and convenient and can become a genetic operating measure of an environmental microorganism, namely pseudomonas putida KT2440 which has important application value in the aspects of organic compound biodegradation and the like.

The present invention belongs to the field of antibiotic gene engineering, and is especially the process of cloning nicomycin biological synthetic gene sanU from one strain of Streptomyces ansochromogenes 7100 CGMCC 4.321; connecting the synthetic gene sanU with promoter of melanin biosynthetic structure gene, cloning onto the polycloning site of integrative single-copy plamid, transforming wild Streptomyces ansochromogenes 7100 CGMCC 4.321 protoplast to obtain nicomycin X component of the recombinant engineering bacterium in the yield 2 times higher than wild strain. The high-yield engineering bacterium may be used in preparing antiseptic medicines.

The invention discloses an expressing and purifying method of a recombinant human-derived LECT2 protein in Pichia pastoris, and the method is characterized by comprising the following steps of: inserting an artificially synthesized human-derived LECT2 gene into an extracellular expression vector pPICZalphaA to construct a recombinant expression plasmid; carrying out enzyme digestion and linearization, then carrying out electric shock, and introducing the recombinant expression plasmid to Pichia pastoris X33 to obtain a recombinant engineering gene; carrying out shake flask fermentation and methanol induction to realize secretory expression of the recombinant human-derived LECT2 protein; and then, purifying by utilizing column chromatography to prepare the recombinant human-derived LECT2 protein with the purity of over 95%. The expressing and purifying method of the recombinant human-derived LECT2 protein in Pichia pastoris has the advantages that the secretory expressing and purifying method of the recombinant human-derived LECT2 protein in Pichia pastoris is firstly proposed, a great number of recombinant human-derived LECT2 proteins with high activity are expressed by using the Pichia pastoris, and the expressing and purifying method has the advantages of stability, high yield, high activity and the like and can be used for pharmacy and diagnosis detection.

The invention discloses engineering bacteria of soluble expression Not I, and a construction method and application thereof. The engineering bacteria of the invention comprises methylase Eag I M gene, restriction enzyme Not I gene and escherichia coli (E. coli) ER2566 (mcrC-mrr). After separating and identifying the Not I gene, the invention obtains the engineering bacteria of efficient soluble expression Not I through the reconstruction of the recombinant. In the invention, the Not I restriction enzyme with high purity can be prepared through groping the inducement conditions of recombining the engineering bacteria and optimizing a protein purification process.

The invention discloses a recombinant human erythropoietin-CTP fusion protein production process. The process is characterized in that a microcarrier suspension perfusion culture technology or a serum-free suspension fed-batch culture technology is adopted as a recombinant engineering cell line culture manner. The invention also discloses a recombinant human erythropoietin-CTP fusion protein purifying process. Through optimization, a simple process flow is obtained, such that high-purity and high-activity recombinant human erythropoietin-CTP fusion protein is obtained. The invention also relates to the ticokinetics study of the recombinant human erythropoietin-CTP fusion protein in monkey bodies, and the application of the recombinant human erythropoietin-CTP fusion protein in treating rat renal anemia.

The invention relates to the field of gene engineering, particularly a high-specific-activity endo-xylanase NPWXynB, and a gene and application thereof. Orthogenesis and site-directed mutagenesis are utilized to perform molecular modification on endo-xylanase XynB derived from rumen fungus Neocallimastix patriciarum to obtain the high-specific-activity xylanase NPWXynB. In the amino acid sequence, the 58th site Y is substituted by F, the 78th site M is substituted by Y, the 94th site Y is substituted by S, the 143rd site V is substituted by L, the 145th site E is substituted by R, and the 182nd site D is substituted by R. The specific activity of the endo-xylanase mutant NPWXynB provided by the invention is 11500 U/mg under the condition of 37 DEG C, which is enhanced by 82.5% as compared with the specific activity of the original endo-xylanase XynB. The maximum enzyme activity of the NPWXynB-gene-containing recombinant engineering bacterium can reach 153000 U/mL, and the production cost is greatly lowered.

The invention relates to the technical field of biomedical engineering, and relates to a method for preparing human parathyroid hormone (1-34) through fermenting and purifying human parathyroid hormone 1-34 recombinant engineering bacteria constructed by a gene engineering method. The method provided by the invention comprises the following steps: fusing and expressing the genes for coding human parathyroid hormone and a thioredoxin label, and further constructing and finishing genetic engineering bacteria capable of highly expressing human parathyroid hormone; adding IPTG (isopropyl beta D thiogalactopy ranoside) and triton X-100 in the fermentation process by adopting a chemosmosis fermentation technology so as to improve the release of proteins extracellularly in the fermentation process, which is good for the continuous synthesis of proteins, and avoiding the attack of endoproteinase, thus protein high-yield extracellular accumulation is promoted; and simultaneously carrying out heat treatment on a fermentation liquid when the fermentation reaches the final point aiming at the heat stability of thioredoxin fusion, thus initially purified target proteins are directly recycled and obtained from a fermentation liquor supernatant after centrifugation.

The invention discloses a gene highly expressing a nuclease P1 and an expression vector and a host cell comprising the gene and an application for the gene. The invention discloses a recombinant pichia yeast CGMCC No.3188 expressing the gene of nuclease P1 produced from Penicillium citrinum and its construction method. The inventive recombinant engineering strain pichia yeast CGMCC No.3188 can highly express Penicillium citrinum nucP gene. The secretion-expressed nuclease P1 has high phosphodiesterase activity, is used for hydrolyzing RNA, has high product yield and little generated impurity and reduces working procedure of downstream separation as well as decreases production cost. The invention uses the recombinant engineering strain pichia yeast CGMCC No.3188 to perform high density fermentation. The enzyme activity is 1.5 times by the wild strains. The acquired recombinase is applied to RNA solution enzymatic hydrolysis, thus, reaching the hydrolysis rate of more than 40% and the acquired hydrolysate by-product is substantially reduced.

The invention relates to a method for carrying out gene knock-out or point mutation on a colibacillary genome by an oligonucleotide mediated recombineering measure. The method comprises the following steps: firstly, integrating a gene box of a cane sugar 6-fructosyltransferase gene and a kanamycin resistance gene containing isogenous arms into a target gene through recombineering; and then, carrying out isogenous recombination on oligonucleotide containing the isogenous arms and the isogenous sequences on the genome through the recombineering to remove the cane sugar 6-fructosyltransferase gene and the kanamycin resistance gene. Thereby, the gene knock-out and point mutation without any basic group redundance are realized. The gene knock-out oligonucleotide design conforms to the basic group sequences of both sides of the target genes, and base groups needing the mutation are introduced in the oligonucleotide by the point mutation oligonucleotide. The invention does not need in-vitro clone and in-vitro realization of some basic group bit mutation or mutation gene transplanting into germ bodies. The method of the invention can provide an effective early-stage operation platform for the industrial production and the research such as genetics, molecular biology, biochemistry and the like.

The invention relates to a method for efficient expression preparation of UDP-glucose-hexose-1-phosphate uridyltransferase. According to the method, a recombinant expression vector is constructed fromUDP-glucose-hexose-1-phosphate uridyltransferase (GalT) gene and Bacillus subtilis by using a vector; the recombinant expression vector is transformed into Bacillus subtilis to construct a recombinant engineered strain; the recombinant engineering strain is subjected to induced culture in a liquid culture medium; and the obtained bacterial liquid is subjected to centrifugation, and the supernatant is taken. According to the present invention, the method has advantages of high yield of UDP-glucose-hexose-1-phosphate uridyltransferase, pure protein, easy recovery and purification and simple production operation, provides the convenience in the industrial large-scale production of GalT, further has advantages of yield improving, time saving, labor saving and cost saving, particularly provides the safety assurance in the application of the enzyme in the food industry, and has great significance.

The invention relates to the field of genetic engineering, and in particular to an alpha-AmyL (Amylase) mutant with increased activity and a coding gene and application thereof. An amino acid sequence of the mutant is as shown in SEQ ID NO. 2. The fermentation enzyme activity of an improved alpha-AmyL strain is up to 36900 U/mL, and compared with an alpha-AmyL producing strain before improvement, the fermentation enzyme activity is increased by 41.5 percent. According to mutant BsaAmy6 (Bacillus Salsus Alpha-Amylase 6) and recombinant engineering bacterium, the fermentation production cost is greatly reduced, and a foundation is laid for further industrial application.

The invention discloses a fusion protein for expressing recombinant parathyroid hormone (PTH). The fusion protein is sequentially composed of an expression enhancing peptide, a connecting peptide 1, His6, a connecting peptide 2, a guide protein, a connecting peptide 3, a protease cleavage site and parathyroid hormone (PTH) (1-34). The invention also provides recombinant plasmids and engineering bacteria for expressing the fusion protein of the recombinant parathyroid hormone PTH. According to the invention, the fusion protein expressed by an approximate inclusion body and a stable recombinantengineering strain can be obtained. Through protease digestion of the expression protein and purification of a few steps, the target protein PTH (1-34) with purity higher than 99.5% and good biological activity can be obtained.